Skip to main content

Advertisement

Table 1 Study endpoints based on symptoms

From: Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold

End point Carrageenan nasal spray n = 14 Placebo nasal spray n = 18 p-value
Primary endpoint    
TSS mean of sum on days 2-4 4.62 ± 2,06 6.28 ± 2.29 0.046
Secondary endpoints    
LSS mean of sum on days 2-4 3.79 ± 2,03 5.22 ± 2.30 0.068
SSS mean of sum on days 2-4 0.83 ± 0,75 1.06 ± 1,07 0.704
  1. Shown are symptom scores TSS (total symptom score), LSS (local symptom score), and SSS (systemic symptom score) ± standard deviation.